KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Accuray (ARAY) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Accuray (ARAY) over the last 16 years, with Q4 2025 value amounting to $1.2 million.

  • Accuray's Asset Writedowns and Impairment changed N/A to $1.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 million, marking a year-over-year decrease of 2214.09%. This contributed to the annual value of $2.2 million for FY2025, which is 6320.16% down from last year.
  • Accuray's Asset Writedowns and Impairment amounted to $1.2 million in Q4 2025.
  • In the past 5 years, Accuray's Asset Writedowns and Impairment registered a high of $4.6 million during Q1 2021, and its lowest value of $769000.0 during Q3 2022.
  • Its 5-year average for Asset Writedowns and Impairment is $1.8 million, with a median of $1.2 million in 2023.
  • The largest annual percentage gain for Accuray's Asset Writedowns and Impairment in the last 5 years was 58056.8% (2021), contrasted with its biggest fall of 5625.0% (2021).
  • Quarter analysis of 5 years shows Accuray's Asset Writedowns and Impairment stood at $868000.0 in 2021, then soared by 38.59% to $1.2 million in 2022, then increased by 6.48% to $1.3 million in 2023, then decreased by 28.73% to $913000.0 in 2024, then soared by 32.75% to $1.2 million in 2025.
  • Its Asset Writedowns and Impairment stands at $1.2 million for Q4 2025, versus $1.0 million for Q3 2025 and $2.3 million for Q1 2025.